Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

Subrahmanyam Vangala

Subrahmanyam Vangala

CEO and Co founder
ReaGene Biosciences Private Limited
India

Biography

Dr. Subrahmanyam Vangala is currently Founder and Chief Executive Officer at ReaGene Biosciences Private Limited (Bangalore, India). He is an experienced pharma scientist and executive with more than two decades of leadership experience with increasing responsibilities, at global pharma in USA (Wyeth, JNJ, Purdue Pharma and the Shire) and Contract Research Organizations in India (Sai Life and Advinus). He received his Ph.D. Degree in Biochemical Mechanisms of Chemical Carcinogenesis from the Department of Biochemistry, Memorial University of Newfoundland, Canada. He conducted his postdoctoral research in Molecular Toxicology department at University of Colorado at Boulder and continued as a Specialist Scientist (Research Assistant Professor) in Molecular Toxicology at School of Public Health, University of California, Berkeley. Extensive experience in leading DMPK/ADME and Toxicology departments including Clinical Pharmacology, Bioanalytical and Electronic Documentation groups. Managed up to 75 personnel (Research Scientist to Senior Director levels). Built infrastructures from scratch. Supported pharmacokinetics, toxicokinetics, drug metabolism, drug-drug interactions, in-silico modeling, allometric scaling and first-in-human dosing projections, mechanistic pharmacology/toxicology, pharmacogenomics/ toxicogenomics/metabolomics, genetic toxicology, high-resolution mass spectrometry for metabolite identification, pre-formulation development, 3D model development. Prepared short term and long term business plans, budgets, proactively identified road bumps and collaborated extensively with other departments to prepare and execute remedial action plans. He brings with him, unique insights into translational research. He is on the scientific advisory board of Bioagile therapeutics and on the editorial board of journals related to toxicology and analytical research. He has 50 plus peers reviewed publications in peer-reviewed journals including invited book chapters. He has chaired several international symposia in predictive toxicology, idiosyncratic drug toxicity, and DMPK. Served as an editorial board member for international journals. Currently serving as a chief scientific advisor for Bioagile Therapeutics, Trana Labs and Care hospitals. Selected to the expert committee panel for ICMR (Indian Council of Medical Research) on non-animal technologies and prepared a white paper along with other core expert team members. His Current research interests include developing in vitro 3D human models of translational pharmacology and toxicology research for improved clinical translation and use as alternatives to animals in research. Applications of OMICS (Genomics and Metabolomics) with human 3D models to support precision medicine concepts.

Research Interest

His Current research interests include developing in vitro 3D human models of translational pharmacology and toxicology research for improved clinical translation and use as alternatives to animals in research. Applications of OMICS (Genomics and Metabolomics) with human 3D models to support precision medicine concepts.